Enavate Sciences GP, LLC reported 7 positions worth $345.38M for the quarter ended Jun 30, 2026, down 1.7% on the prior quarter. It opened 0 new positions, added to 0, trimmed 1 and exited 0. Its largest holding is Sionna Therapeutics, Inc. at 31.6% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
No positions were added to this quarter.
| Holding | Change | Trade Value | Weight |
|---|---|---|---|
| CAMP Camp4 Therapeutics Corp | -765.4K -34.9% | $3.34M | 1.8% |
No new positions this quarter.
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | SION Sionna Therapeutics, Inc. | Healthcare | 2.48M | $109.01M | 31.56% | 0 | 0.0% | Unchanged | 5.49% |
| 2 | ZBIO Zenas BioPharma, Inc. | Healthcare | 3.92M | $99.47M | 28.8% | 0 | 0.0% | Unchanged | 6.19% |
| 3 | IMNM Immunome Inc. | Healthcare | 3.61M | $76.58M | 22.17% | 0 | 0.0% | Unchanged | 3.19% |
| 4 | BBOT BridgeBio Oncology Therapeutics, Inc. | Healthcare | 2.63M | $20.02M | 5.8% | 0 | 0.0% | Unchanged | 3.28% |
| 5 | CMPX Compass Therapeutics, Inc. | Healthcare | 7.79M | $17.06M | 4.94% | 0 | 0.0% | Unchanged | 4.17% |
| 6 | UPB Upstream Bio, Inc. | Healthcare | 2.46M | $17.02M | 4.93% | 0 | 0.0% | Unchanged | 4.49% |
| 7 | CAMP Camp4 Therapeutics Corp | Healthcare | 1.43M | $6.23M | 1.8% | -765.4K | -34.9% | Reduced | 2.46% |
Tip. Select a row to see that position’s full history at Enavate Sciences GP.
As of its Q2 2026 13F filing, Enavate Sciences GP, LLC’s five largest positions were Sionna Therapeutics, Inc. (SION) at 31.6%, Zenas BioPharma, Inc. (ZBIO) at 28.8%, Immunome Inc. (IMNM) at 22.2%, BridgeBio Oncology Therapeutics, Inc. (BBOT) at 5.8%, Compass Therapeutics, Inc. (CMPX) at 4.9% of the reported portfolio.
Enavate Sciences GP, LLC reported a 13F portfolio worth $345.38M across 7 positions for Q2 2026. That is down 1.7% from the previous quarter.
Its largest sales by value were Camp4 Therapeutics Corp ($3.34M). It exited 0 positions entirely.
From the Form 13F-HR reports Enavate Sciences GP, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.